Wisdom Engraced
Keep up with the latest news and be part of our weekly giveaways and airtime sharing; follow our WhatsApp channel for more updates. Click to Follow us
Owlstone Medical, a biotech company based in Cambridge, England, has secured an investment of up to £1.7 million ($2.3 million) from the Cystic Fibrosis Foundation. The funding will support the development of a breath test to detect Pseudomonas aeruginosa (PA) in cystic fibrosis (CF) patients.
For further information, read more details here
Cystic fibrosis is a progressive genetic disorder characterised by excessive mucus production, which traps pathogens in the lungs. PA affects an estimated 25% of CF patients and is challenging to eliminate once established.
The investment will enable Owlstone Medical to develop easy-to-administer breath tests for both early detection of new PA infections and monitoring of chronic infections in CF patients. According to Billy Boyle, Owlstone Medical’s co-founder and CEO, “Owlstone’s experience in the breath-based detection of infectious disease… places Owlstone in an excellent position to help improve outcomes for CF patients infected with Pseudomonas aeruginosa.”
The development of this breath test aims to improve the detection and management of PA infections in CF patients, potentially leading to better health outcomes
Please don’t forget to “Allow the notification” so you will be the first to get our gist when we publish it.
Drop your comment in the section below, and don’t forget to share the post
